Gadoteridol is a paramagnetic contrast agent indicated for magnetic resonance imaging (MRI) to visualize, among other approved uses. It is available as injection for intravenous use. MedsAcross supplies Gadoteridol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ProHance is a gadolinium-based contrast agent indicated for magnetic resonance imaging (MRI) to visualize: lesions with disrupted blood brain barrier and/or abnormal vascularity in the brain (intracranial lesions), spine and associated tissues in adults and pediatric patients, including term neonates lesions in the head and neck in adults
Source: US FDA prescribing information
Gadoteridol is a paramagnetic agent and, as such, develops a magnetic moment when placed in a magnetic field. The relatively large magnetic moment produced by the paramagnetic agent results in a relatively large local magnetic field, which can enhance the relaxation rates of water protons in the vicinity of the paramagnetic agent. In MRI, visualization of normal and pathologic brain tissue depends, in part, on variations in the radiofrequency signal intensity that occur with: 1) differences in proton density, 2) differences of the spin-lattice or longitudinal relaxation times (T1), and 3) differences in the spin-spin or transverse relaxation time (T2). When placed in a magnetic field, gadoteridol decreases T1 relaxation times in the target tissues. At recommended doses, the effect is observed with greatest sensitivity in the T1-weighted sequences.
Source: US FDA prescribing information
Recommended dose in adult and pediatric patients is 0.2 mL/kg (0.1 mmol/kg) body weight administered as rapid intravenous infusion or bolus. Follow injection with a saline flush of at least 5 mL normal saline
Source: US FDA prescribing information
ProHance is contraindicated in patients with known allergic or hypersensitivity reactions to ProHance. Allergic or hypersensitivity reactions to ProHance
Source: US FDA prescribing information
Boxed warning (risk associated with intrathecal use and nephrogenic systemic fibrosis): Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. ProHance is not approved for intrathecal use. Hypersensitivity: anaphylactic/anaphylactoid reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe reactions including shock can occur. Monitor patients closely for need of emergency cardiorespiratory support. Gadolinium is retained for months or years in brain, bone, and other organs.
Source: US FDA prescribing information
The following serious adverse reactions are discussed in greater detail in other sections of the prescribing information: Nephrogenic systemic fibrosis Hypersensitivity reactions The most commonly reported adverse reactions are nausea and taste perversion with an incidence ≥ 0.9%
Source: US FDA prescribing information
Store at 25°C (77° F). Excursions permitted to 15°C to 30°C (59°F to 86°F). DO NOT FREEZE. Should freezing occur in the vial, ProHance should be brought to room temperature before use. If allowed to stand at room temperature for a minimum of 60 minutes, ProHance should return to a clear, colorless to slightly yellow solution. Protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
10 presentations of Gadoteridol, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Gadoteridol 1396.5 mg/5 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Gadoteridol 2793 mg/10 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Gadoteridol 4189.5 mg/15 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Gadoteridol 5586 mg/20 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| ProHance 1396.5 mg/5 mL injectionIntravenous | Bracco Diagnostics | US FDA | Available on request |
| ProHance 13965 mg/50 mL injectionIntravenous | Bracco Diagnostics | US FDA | Available on request |
| ProHance 2793 mg/10 mL injectionIntravenous | Bracco Diagnostics | US FDA | Available on request |
| ProHance 27930 mg/100 mL injectionIntravenous | Bracco Diagnostics | US FDA | Available on request |
| ProHance 4189.5 mg/15 mL injectionIntravenous | Bracco Diagnostics | US FDA | Available on request |
| ProHance 5586 mg/20 mL injectionIntravenous | Bracco Diagnostics | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 16 November 1992 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 10 presentations of Gadoteridol and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Gadoteridol, including ProHance.
Yes. The US FDA first approved Gadoteridol on 16 November 1992, according to Drugs@FDA.
No listed presentation of Gadoteridol is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Gadoteridol is classified under ATC code V08CA04 (Gadoteridol).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.